News
Public · Published
BTIG maintains United Therapeutics at Buy, raises price target to $768 from $728
BTIG kept its Buy rating on United Therapeutics and raised its price target to $768 from $728, a 5.5% increase. The target is 27.7% above the stock's Nov. 3 closing price of $601.32.
Published:
Updated:
What happened
BTIG kept its Buy rating on United Therapeutics and raised its price target to $768 from $728, a 5.5% increase. The target is 27.7% above the stock’s Nov. 3 closing price of $601.32.
Confirmed
Global impact / market context
The higher target signals BTIG expects more share-price upside than its prior estimate, but it does not change the company’s sales, costs, or cash directly. If investors act on the view, buying or selling could affect the stock price without guaranteeing that target is reached.
Analyst inference
The four other analyst notes listed from the past 30 days have targets ranging from $566 to $725, below BTIG’s new $768 target. That puts BTIG’s view above this small group, while showing analysts do not share one valuation estimate.
Confirmed
What to watch
- Watch for United Therapeutics’ next reported business results: revenue, costs, and cash generation could help investors judge whether the share-price optimism is supported by company performance. Analyst inference
- Check whether other analysts change their ratings or price targets. Broader revisions toward BTIG’s higher target would indicate a shift in expectations, while lower targets would show continued disagreement. Analyst inference
- BTIG’s stated action is a maintained Buy rating and a raised target to $768 from $728; the article does not report a company announcement or operational change. Confirmed
Evidence
- Original source link unavailable